• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Ariad Pharmaceuticals

Ariad Pharmaceuticals

  1. All
  2. 3rd Party
  1. ARIAD Announces FDA Full Approval and Label Update for Iclusig® (ponatinib) Based on Long-Term Efficacy and Safety Data from Phase 2 PACE Clinical Trial

    ARIAD Announces FDA Full Approval and Label Update for Iclusig® (ponatinib) Based on Long-Term Efficacy and Safety Data from Phase 2 PACE Clinical Trial

  2. The Top-Performing Funds in 2011's Toughest Category

    These two small-value funds have followed different paths to success in a difficult year for the peer group.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.